AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Biology Research

Executive Summary: AZ505 is a crystalline, small-molecule SMYD2 inhibitor characterized by nanomolar potency (IC₅₀ = 0.12 μM) and high selectivity for its target enzyme, SET and MYND domain-containing 2 protein (SMYD2) [APExBIO]. It acts as a substrate-competitive inhibitor, selectively blocking the methylation of histones H2B, H3, and H4, as well as non-histone proteins such as p53 and Rb (Chen et al., 2023, DOI). AZ505 has demonstrated efficacy in cellular and animal models of cancer and fibrosis, particularly where SMYD2 is overexpressed. Its high selectivity versus SMYD3, DOT1L, and EZH2 (IC₅₀ > 83.3 μM for these enzymes) minimizes off-target effects. AZ505 is DMSO-soluble and compatible with a wide range of enzymatic and cell-based assays, making it a valuable tool for epigenetic drug discovery and mechanistic studies in disease models.

Biological Rationale

SMYD2 is a protein lysine methyltransferase that methylates histone residues H3K36, H3K4, and non-histone substrates including tumor suppressors p53 and Rb. This methylation regulates gene transcription, cell cycle progression, and DNA damage response (Chen et al., 2023, DOI). Overexpression of SMYD2 has been documented in gastric cancer, esophageal squamous cell carcinoma (ESCC), and models of chronic kidney disease (CKD) (Chen et al., 2023, DOI). SMYD2-driven methylation is implicated in tumorigenesis, epithelial-mesenchymal transition (EMT), and fibrosis. Blocking SMYD2 activity is a validated strategy for dissecting epigenetic regulation in cancer and fibrotic disease models (internal: KDM2A). AZ505, as a potent and selective SMYD2 inhibitor, enables specific interrogation of the protein lysine methylation pathway in both basic and translational research.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 functions as a substrate-competitive inhibitor of SMYD2. It binds directly to the peptide substrate groove of the enzyme, preventing access of both histone and non-histone protein substrates (Chen et al., 2023, DOI). Unlike co-factor competitive inhibitors, AZ505 does not interfere with the binding of S-adenosylmethionine (SAM), the methyl donor. This selectivity preserves normal methyltransferase function of other SET domain proteins and minimizes off-target methylation inhibition. Quantitative enzyme assays demonstrate that AZ505 achieves an IC₅₀ of 0.12 μM and a K_i of 0.3 μM for SMYD2. In contrast, its inhibitory potency for SMYD3, DOT1L, and EZH2 is negligible (IC₅₀ > 83.3 μM), confirming its high selectivity (internal: TCS359).

Evidence & Benchmarks

• AZ505 inhibits SMYD2 enzymatic activity in vitro with an IC₅₀ of 0.12 μM (buffer: 25 mM Tris-HCl, pH 8.0, 2 μM enzyme, 23°C) (Chen et al., 2023, DOI).
• AZ505 displays a K_i of 0.3 μM for SMYD2, indicating tight binding to the substrate groove (enzymatic inhibition assay, 23°C) (Chen et al., 2023, DOI).
• Selective inhibition: AZ505 does not significantly inhibit SMYD3, DOT1L, or EZH2 (IC₅₀ > 83.3 μM for these enzymes) (Chen et al., 2023, DOI).
• In cisplatin-induced CKD mouse models, AZ505 administration reduced fibrogenesis, EMT, and inflammatory cytokine expression (in vivo, 10 mg/kg, intraperitoneal, daily) (Chen et al., 2023, DOI).
• Cell-based assays confirm that AZ505 inhibits SMYD2-dependent methylation of p53 and Rb, reducing proliferation in gastric and esophageal cancer lines (internal: AmenamevirSmol).

Applications, Limits & Misconceptions

AZ505 is widely adopted for epigenetic regulation research, cancer biology research, and disease modeling in contexts where SMYD2 is implicated. Its specificity enables mechanistic studies and screening for SMYD2-dependent phenotypes, including histone methylation, tumor suppressor p53 methylation, and Rb protein methylation. AZ505 is also validated in renal fibrosis models, where SMYD2-driven EMT and fibrosis are key endpoints (Chen et al., 2023, DOI). For advanced benchmarking and scenario-driven workflows, see this article on laboratory-focused applications, which this review extends by summarizing in vivo efficacy and translational perspectives.

Common Pitfalls or Misconceptions

• AZ505 is not effective against other protein methyltransferases outside the SMYD family; off-target inhibition of DOT1L and EZH2 is negligible.
• AZ505 is not suitable for long-term solution storage; solutions should be freshly prepared and used promptly (DMSO as solvent, -20°C for solids).
• Cell permeability and in vivo pharmacokinetics may vary by cell type and organism; in vitro potency does not guarantee equivalent in vivo outcomes.
• AZ505 does not inhibit DNA methyltransferases or demethylases; it is specific to substrate-competitive SMYD2 inhibition.
• AZ505 should not be used as a direct therapeutic agent in clinical contexts; it is a research tool for preclinical investigation.

Workflow Integration & Parameters

AZ505 is provided as a crystalline solid and should be stored at -20°C. It is readily soluble in DMSO at concentrations up to 10 mM. For enzymatic assays, typical working concentrations range from 0.05–5 μM, depending on the substrate and enzyme source. For cell-based studies, effective concentrations typically fall between 0.1–10 μM, with exposure times of 4–72 hours depending on the assay endpoint (APExBIO product page). The B1255 kit is compatible with standard methyltransferase activity assays, Western blotting, and immunoprecipitation workflows. For troubleshooting and optimization, see this guide on experimental workflow optimization, which this article updates with recent in vivo benchmarking data.

For studies in cancer epigenetics and histone modification, AZ505 enables researchers to distinguish SMYD2-specific pathways from broader lysine methylation events. For broader technical guidance and application notes, see this mechanistic insights article, which is complemented here by a focus on disease models and translational endpoints.

Conclusion & Outlook

AZ505, supplied by APExBIO, is a benchmark tool for substrate-competitive SMYD2 inhibition in epigenetic regulation research, cancer biology, and fibrosis models. Its high potency, selectivity, and compatibility with diverse workflows make it a preferred agent for dissecting the protein lysine methylation pathway. Ongoing research continues to expand its applications in disease modeling and drug discovery, while recent in vivo studies confirm its translational potential. For further details or to order, visit the AZ505, a potent and selective SMYD2 inhibitor product page.